Erlotinib in second-line therapy for non-small cell lung cancer - A clinical case.
the epidermal growth-factor receptor (EGFR) and its signaling pathway have become a major target for therapy of non-small cell lung cancer (NSCLC). After the BR.21 study showed its effectiveness and its tolerability in older patients, erlotinib, a specific EGFR tyrosine-kinase inhibitor, has been approved for NSCLC therapy after failure of treatment with at least one line of chemotherapy (CT). The authors present the case of a 63 years-old female patient, with a history of angina pectoris, who was diagnosed with a lung adenocarcinoma. Because of poor tolerance to first-line CT, she had second-line treatment with erlotinib. There was a good response to therapy, along with symptomatic improvement. Adverse effects were light to moderate, well tolerated, and required no dose reduction. Rev Port Pneumol 2008; XIV (Supl 3): S17-S22.